Acuta Capital Partners LLC Acquires Shares of 73,500 Liquidia Co. (NASDAQ:LQDA)

Acuta Capital Partners LLC bought a new position in shares of Liquidia Co. (NASDAQ:LQDA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 73,500 shares of the company’s stock, valued at approximately $735,000. Liquidia makes up approximately 0.6% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 28th largest position. Acuta Capital Partners LLC owned about 0.10% of Liquidia as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after buying an additional 43,352 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Liquidia during the first quarter worth approximately $30,311,000. Charles Schwab Investment Management Inc. increased its position in shares of Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after purchasing an additional 230,820 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock valued at $2,496,000 after purchasing an additional 32,076 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Liquidia by 735.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after purchasing an additional 123,402 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Stock Up 1.7 %

LQDA stock opened at $11.61 on Thursday. Liquidia Co. has a 52-week low of $6.82 and a 52-week high of $16.99. The stock has a market cap of $982.64 million, a price-to-earnings ratio of -7.12 and a beta of 0.21. The business has a fifty day moving average of $10.67 and a two-hundred day moving average of $11.36.

Insider Transactions at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the transaction, the insider now owns 204,857 shares of the company’s stock, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Caligan Partners Lp purchased 150,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were bought at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the transaction, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. The trade was a 2.19 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 21,551 shares of company stock worth $236,021. 30.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital began coverage on shares of Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective for the company. Bank of America decreased their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Liquidia in a research report on Thursday, November 14th. Finally, Scotiabank assumed coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).